DiaGen AI  /  Investors

Investing in Tech-Bio at the AI inflection point.

Two validated AI platforms, active partner deployments, and a capital-light structure built to scale. Download the deck for the full investment case.

Investor materials

DiaGen AI · Investor deck

Platform, pipeline, and the case for tech-bio.

Company overview, platform validation, active partnerships, pipeline progress and the capital structure — in one deck.

Download the deck
2Validated AI platforms
7Active partnerships
4Regions: NA / EU / MENA / APAC
6.75MMolecules in the foundation model

Why DiaGen

A capital-light structure built to scale.

DiaGen keeps the models proprietary while pushing synthesis cost onto institutional partners and compute cost onto an incentivized network — shifting spend from fixed infrastructure to variable and performance-based.

Externally validated

Results come back from partner labs with no stake in the model performing well — not from benchmarks DiaGen wrote itself.

Revenue-generating deployment

Both platforms are in active partner deployment today, with revenue-share and co-development agreements already signed.

IP retained

DiaGen retains or co-owns the high-value intellectual property generated across its partner network.

Tech-Bio Partnering: Tools and Deployment

For platform access, catalog partnering or co-development enquiries.

IR@diagen.ai